Quantcast

Latest Rosiglitazone Stories

173a18ddb9388dbd18360bf112619c0f1
2010-09-23 14:20:00

European regulators say that widely-used diabetes drug Avandia should be pulled from the market, but U.S. officials have allowed it to stay. The U.S. Food and Drug Administration in Washington and the European Medicines Agency (EMA) said in separate statements that they agreed on the risks associated with the drug but had reached different conclusions on action. Avandia was once Glaxo's second-biggest selling drug, but sales have dropped in recent years. "The decisions are not surprising,...

2010-09-23 10:48:00

LONDON, Sept. 23 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE and LSE: GSK) confirms that following a review of Avandia® (rosiglitazone maleate) by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), each agency has today announced their individual regulatory decisions and the resulting actions. In the European Union*, the EMA has suspended the marketing authorization for all rosiglitazone-containing medicines (Avandia,...

2010-09-23 10:25:00

Makes regulatory decisions on RECORD and TIDE trials SILVER SPRING, Md., Sept. 23 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced that it will significantly restrict the use of the diabetes drug Avandia (rosiglitazone) to patients with Type 2 diabetes who cannot control their diabetes on other medications. These new restrictions are in response to data that suggest an elevated risk of cardiovascular events, such as heart attack and stroke, in patients...

2010-09-21 10:00:00

BURLINGTON, Mass., Sept. 21 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of key agents such as Merck's Januvia, Eli Lilly/Amylin/Alkermes' Bydureon and Amylin/Eli Lilly's Byetta will drive the type 2 diabetes drug market to nearly double from $19 billion in 2009 to $36 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. The...

2010-09-17 13:05:00

FDA NOTE TO CORRESPONDENTS SILVER SPRING, Md., Sept. 17 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced it has begun a safety review of the diabetes drug Actos (pioglitazone), after receiving preliminary results from a long-term observational study designed to evaluate the risk of bladder cancer associated with use of this drug. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) The...

2010-08-24 15:00:00

Study highlights: A new analysis of data on patients covered by a single insurance company reports that risks of heart disease events and death were no different between patients who took the diabetes drugs rosiglitazone or pioglitazone. In this analysis, approximately 4 percent of patients taking either drug - sold as Avandia and Actos - suffered a heart attack, heart failure, both or died over a 33-month period. See links below to the American Heart Association's statement on TZDs and...

2010-07-29 13:59:58

Fracture risk increases with dose Postmenopausal women with diabetes taking thiazolidinediones (TZDS), including rosiglitazone and pioglitazone, may be at increased risk for fractures according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). Men with diabetes taking both loop diuretics and TZDs may also be at increased risk of fractures. "Our study shows that increased fracture risk is associated with higher TZD...

2010-07-22 12:32:13

Discovery raises possibility of safer, more selective diabetes drugs A new understanding of insulin resistance and the action of diabetes drugs such as Avandia and Actos could pave the way for improved medications that are more selective and safer, say scientists from Dana-Farber Cancer Institute and The Scripps Research Institute. "Our findings strongly suggest that good and bad effects of these drugs can be separated by designing second-generation drugs that focus on the newly uncovered...

815831c2f7b1a24cd3c41f381562448f1
2010-07-22 07:50:00

Federal health authorities are prohibiting new patients from enrolling in a safety study for GlaxoSmithKline's controversial diabetes pill Avandia, a week after an expert panel ruled that the drug increases heart risks. The Associated Press (AP) reported Wednesday that the Food and Drug Administration (FDA) said it issued a "partial clinical hold" on the study to update researchers on the latest concerns about the drug, which has been under a close eye since 2007. Although the panel of...

2010-07-15 14:42:26

The Endocrine Society, American Diabetes Association and American Association of Clinical Endocrinologists issue joint statement in response to an FDA panel's recommendation to keep rosiglitazone (Avandia) on the market The U.S. Food and Drug Administration's (FDA) Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee has completed their evaluation of the scientific research available on the safety of rosiglitazone....


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.